Galmed Pharmaceuticals (NASDAQ:GLMD) Issues Quarterly Earnings Results

Galmed Pharmaceuticals (NASDAQ:GLMD) issued its earnings results on Wednesday. The biopharmaceutical company reported ($2.86) EPS for the quarter, topping analysts’ consensus estimates of ($3.12) by $0.26, FiscalAI reports.

Galmed Pharmaceuticals Price Performance

NASDAQ GLMD traded up $0.18 during trading on Wednesday, hitting $4.10. The company’s stock had a trading volume of 14,484 shares, compared to its average volume of 181,474. The company has a market cap of $4.27 million, a PE ratio of -0.56 and a beta of 0.74. Galmed Pharmaceuticals has a fifty-two week low of $3.29 and a fifty-two week high of $13.20. The business’s 50 day simple moving average is $4.43 and its 200-day simple moving average is $4.75.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 76.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Galmed Pharmaceuticals has a consensus rating of “Sell”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.